Overview
Aliquot publishes the study type and boundaries while withholding a compound half-life and any clinical interpretation.
The reviewed study describes human administration and growth-hormone response. Aliquot withholds a compound half-life because the source does not provide a route-specific elimination estimate.
Human pharmacokinetic context
Not published
Aliquot has not published a route-matched human half-life statement for this entry.
Half-life is descriptive population context, not a dosing interval, a prediction of an individual's response, or a recommendation. Route-mismatched and uncited estimates are withheld.
Limitations
- The reviewed study is older and included 12 healthy young volunteers.
- Hormone-response timing is not the pharmacokinetic half-life of hexarelin.
- The study does not support a modern approval, outcome, or dosing statement.
- No U.S. approval conclusion is inferred from a database search.
Related calculation tools
Aliquot's browser-only tools transform values you already have. They do not select a compound, suggest an amount, provide presets, or store your entries.
Sources
- Growth hormone-releasing activity of hexarelin after intravenous, subcutaneous, intranasal, and oral administration in man Limited human research across intravenous, subcutaneous, intranasal, and oral administration.
- Drugs@FDA: FDA-approved drugs Regulatory database consulted; no compound-specific approval conclusion is asserted.
- Aliquot compound library methodology Editorial scope and withholding rules.